Matthew K. Szot - 27 Aug 2025 Form 4 Insider Report for Cadrenal Therapeutics, Inc. (CVKD)

Role
Chief Financial Officer
Signature
/s/ Matthew K. Szot
Issuer symbol
CVKD
Transactions as of
27 Aug 2025
Net transactions value
-$27,992
Form type
4
Filing time
29 Aug 2025, 20:35:16 UTC
Previous filing
28 Aug 2025
Next filing
26 Sep 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Szot Matthew K Chief Financial Officer C/O CADRENAL THERAPEUTICS, INC.,, 822 A1A NORTH, SUITE 306, PONTE VEDRA /s/ Matthew K. Szot 29 Aug 2025 0001401385

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CVKD Common Stock Sale $22,392 -1,600 -4.8% $14.00 31,733 27 Aug 2025 Direct F1
transaction CVKD Common Stock Sale $5,600 -400 -1.3% $14.00 31,333 28 Aug 2025 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.99 through $14.00. The reporting person undertakes to provide to Cadrenal Therapeutics, Inc., any security holder of Cadrenal Therapeutics, Inc. or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions, each at $14.000. The reporting person undertakes to provide to Cadrenal Therapeutics, Inc., any security holder of Cadrenal Therapeutics, Inc. or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.